Top

Current Osteoporosis Reports

Published in:

Open Access 01-06-2018 | Orthopedic Management of Fractures (S Bukata and L Gerstenfeld, Section Editors)

Anabolic Strategies to Augment Bone Fracture Healing

Authors: Scott J. Roberts, Hua Zhu Ke

Published in: Current Osteoporosis Reports | Issue 3/2018

Abstract

Purpose of Review

The development of therapeutics that target anabolic pathways involved in skeletogenesis is of great importance with regard to disease resulting in bone loss, or in cases of impaired bone repair. This review aims to summarize recent developments in this area.

Recent Findings

A greater understanding of how drugs that modulate signaling pathways involved in skeletogenesis exert their efficacy, and the molecular mechanisms resulting in bone formation has led to novel pharmacological bone repair strategies. Furthermore, crosstalk between pathways and molecules has suggested signaling synergies that may be exploited for enhanced tissue formation.

Summary

The sequential pharmacological stimulation of the molecular cascades resulting in tissue repair is a promising strategy for the treatment of bone fractures. It is proposed that a therapeutic strategy which mimics the natural cascade of events observed during fracture repair may be achieved through temporal targeting of tissue repair pathways.

Ferguson C, Alpern E, Miclau T, Helms JA. Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev. 1999;87(1–2):57–66.CrossRefPubMed

Vortkamp A, Pathi S, Peretti GM, Caruso EM, Zaleske DJ, Tabin CJ. Recapitulation of signals regulating embryonic bone formation during postnatal growth and in fracture repair. Mech Dev. 1998;71(1–2):65–76.CrossRefPubMed

Fong K, Truong V, Foote CJ, Petrisor B, Williams D, Ristevski B, et al. Predictors of nonunion and reoperation in patients with fractures of the tibia: an observational study. BMC Musculoskelet Disord. 2013;14:103. https://doi.org/10.1186/1471-2474-14-103.CrossRefPubMedPubMedCentral

Bishop JA, Palanca AA, Bellino MJ, Lowenberg DW. Assessment of compromised fracture healing. The Journal of the American Academy of Orthopaedic Surgeons. 2012;20(5):273–82. https://doi.org/10.5435/JAAOS-20-05-273.CrossRefPubMed

Santolini E, West R, Giannoudis PV. Risk factors for long bone fracture non-union: a stratification approach based on the level of the existing scientific evidence. Injury. 2015;46(Suppl 8):S8–S19. https://doi.org/10.1016/S0020-1383(15)30049-8.CrossRefPubMed

Zimmermann G, Wagner C, Schmeckenbecher K, Wentzensen A, Moghaddam A. Treatment of tibial shaft non-unions: bone morphogenetic proteins versus autologous bone graft. Injury. 2009;40(Suppl 3):S50–3. https://doi.org/10.1016/S0020-1383(09)70012-9.CrossRefPubMed

Goulet JA, Senunas LE, DeSilva GL, Greenfield ML. Autogenous iliac crest bone graft. Complications and functional assessment. Clin Orthop Relat Res. 1997;339:76–81.CrossRef

Hegde V, Jo JE, Andreopoulou P, Lane JM. Effect of osteoporosis medications on fracture healing. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2016;27(3):861–71. https://doi.org/10.1007/s00198-015-3331-7.CrossRef

Papakostidis C, Kontakis G, Bhandari M, Giannoudis PV. Efficacy of autologous iliac crest bone graft and bone morphogenetic proteins for posterolateral fusion of lumbar spine: a meta-analysis of the results. Spine. 2008;33(19):E680–92. https://doi.org/10.1097/BRS.0b013e3181844eca.CrossRefPubMed

10.

Garrison KR, Donell S, Ryder J, Shemilt I, Mugford M, Harvey I, et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess. 2007;11(30):1–150. iii-iv CrossRefPubMed

11.

Devine JG, Dettori JR, France JC, Brodt E, McGuire RA. The use of rhBMP in spine surgery: is there a cancer risk? Evid Based Spine Care J. 2012;3(2):35–41. https://doi.org/10.1055/s-0031-1298616.CrossRefPubMedPubMedCentral

12.

Cahill KS, McCormick PC, Levi AD. A comprehensive assessment of the risk of bone morphogenetic protein use in spinal fusion surgery and postoperative cancer diagnosis. J Neurosurg Spine. 2015;23(1):86–93. https://doi.org/10.3171/2014.10.SPINE14338.CrossRefPubMed

13.

Ai-Aql ZS, Alagl AS, Graves DT, Gerstenfeld LC, Einhorn TA. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res. 2008;87(2):107–18. https://doi.org/10.1177/154405910808700215.CrossRefPubMedPubMedCentral

14.

Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracture repair. J Bone Miner Res. 1999;14(11):1805–15. https://doi.org/10.1359/jbmr.1999.14.11.1805.CrossRefPubMed

15.

Cho TJ, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res. 2002;17(3):513–20. https://doi.org/10.1359/jbmr.2002.17.3.513.CrossRefPubMed

16.

Schmid GJ, Kobayashi C, Sandell LJ, Ornitz DM. Fibroblast growth factor expression during skeletal fracture healing in mice. Dev Dyn. 2009;238(3):766–74. https://doi.org/10.1002/dvdy.21882.CrossRefPubMedPubMedCentral

17.

Yu YY, Lieu S, Lu C, Miclau T, Marcucio RS, Colnot C. Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair. Bone. 2010;46(3):841–51. https://doi.org/10.1016/j.bone.2009.11.005.CrossRefPubMed

18.

Roberts SJ, van Gastel N, Carmeliet G, Luyten FP. Uncovering the periosteum for skeletal regeneration: the stem cell that lies beneath. Bone. 2015;70:10–8. https://doi.org/10.1016/j.bone.2014.08.007.CrossRefPubMed

19.

Dong YF, Soung do Y, Schwarz EM, O'Keefe RJ, Drissi H. Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor. J Cell Physiol. 2006;208(1):77–86. https://doi.org/10.1002/jcp.20656.CrossRefPubMed

20.

Chen Y, Whetstone HC, Lin AC, Nadesan P, Wei Q, Poon R, et al. Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med. 2007;4(7):e249. https://doi.org/10.1371/journal.pmed.0040249.CrossRefPubMedPubMedCentral

21.

Wang T, Zhang X, Bikle DD. Osteogenic differentiation of periosteal cells during fracture healing. J Cell Physiol. 2017;232(5):913–21. https://doi.org/10.1002/jcp.25641.CrossRefPubMed

22.

Marsell R, Einhorn TA. The biology of fracture healing. Injury. 2011;42(6):551–5. https://doi.org/10.1016/j.injury.2011.03.031.CrossRefPubMedPubMedCentral

23.

Silva BC, Costa AG, Cusano NE, Kousteni S, Bilezikian JP. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Investig. 2011;34(10):801–10. https://doi.org/10.3275/7925.

24.

Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007;146(5):326–39.CrossRefPubMed

25.

Potts JT Jr, Tregear GW, Keutmann HT, Niall HD, Sauer R, Deftos LJ, et al. Synthesis of a biologically active N-terminal tetratriacontapeptide of parathyroid hormone. Proc Natl Acad Sci U S A. 1971;68(1):63–7.CrossRefPubMedPubMedCentral

26.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41. https://doi.org/10.1056/NEJM200105103441904.CrossRefPubMed

27.

Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997;138(11):4607–12. https://doi.org/10.1210/endo.138.11.5505.CrossRefPubMed

28.

Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y. Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone. 2008;42(1):90–7. https://doi.org/10.1016/j.bone.2007.08.041.CrossRefPubMed

29.

Manabe T, Mori S, Mashiba T, Kaji Y, Iwata K, Komatsubara S, et al. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone. 2007;40(6):1475–82. https://doi.org/10.1016/j.bone.2007.01.015.CrossRefPubMed

30.

Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–14. https://doi.org/10.1359/jbmr.090731.CrossRefPubMed

31.

Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93(17):1583–7. https://doi.org/10.2106/JBJS.J.01379.CrossRefPubMed

32.

Bukata SV, Kaback LA, Reynolds DG, O’Keefe RJ, Rosier RN. 1–34 PTH at physiologic doses in humans shows promise as a helpful adjuvant in difficult to heal fractures: an observational cohort of 145 patients. Presented at the 55th Annual Meeting of the Orthopaedic Research Society Las Vegas, NV; February 25, 2009.

33.

Bukata SV, Puzas JE. Orthopedic uses of teriparatide. Current osteoporosis reports. 2010;8(1):28–33. https://doi.org/10.1007/s11914-010-0006-3.CrossRefPubMed

34.

Chintamaneni S, Finzel K, Gruber BL. Successful treatment of sternal fracture nonunion with teriparatide. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2010;21(6):1059–63. https://doi.org/10.1007/s00198-009-1061-4.CrossRef

35.

Kastirr I, Radmer S, Andresen R, Schober HC. Osseous consolidation of an aseptic delayed union of a lower leg fracture after parathyroid hormone therapy—a case report. J Clin Diagn Res. 2016;10(7):RD03–5. https://doi.org/10.7860/JCDR/2016/20006.8203.PubMedPubMedCentral

36.

Matsumoto T, Ando M, Sasaki S. Effective treatment of delayed union of a lumbar vertebral fracture with daily administration of teriparatide in a patient with diffuse idiopathic skeletal hyperostosis. Eur Spine J. 2015;24(Suppl 4):S573–6. https://doi.org/10.1007/s00586-014-3733-9.CrossRefPubMed

37.

Ochi K, Ikari K, Naomi A, Momohara S. Administration of teriparatide treatment for a challenging case of nonunion of periprosthetic fracture after total knee arthroplasty. Arch Osteoporos. 2013;8:159. https://doi.org/10.1007/s11657-013-0159-7.CrossRefPubMed

38.

Rubery PT, Bukata SV. Teriparatide may accelerate healing in delayed unions of type III odontoid fractures: a report of 3 cases. J Spinal Disord Tech. 2010;23(2):151–5. https://doi.org/10.1097/BSD.0b013e31819a8b7a.CrossRefPubMed

39.

Xiaofeng L, Daxia X, Yunzhen C. Teriparatide as a nonoperative treatment for tibial and femoral fracture nonunion: a case report. Medicine. 2017;96(16):e6571. https://doi.org/10.1097/MD.0000000000006571.CrossRefPubMedPubMedCentral

40.

Fan Y, Hanai JI, Le PT, Bi R, Maridas D, DeMambro V, et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab. 2017;25(3):661–72. https://doi.org/10.1016/j.cmet.2017.01.001.CrossRefPubMedPubMedCentral

41.

Kim SW, Pajevic PD, Selig M, Barry KJ, Yang JY, Shin CS, et al. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. Journal of bone and mineral research. 2012;27(10):2075–84. https://doi.org/10.1002/jbmr.1665.CrossRefPubMedPubMedCentral

42.

Yukata K, Xie C, Li TF, Takahata M, Hoak D, Kondabolu S, et al. Aging periosteal progenitor cells have reduced regenerative responsiveness to bone injury and to the anabolic actions of PTH 1-34 treatment. Bone. 2014;62:79–89. https://doi.org/10.1016/j.bone.2014.02.002.CrossRefPubMedPubMedCentral

43.

Ogura K, Iimura T, Makino Y, Sugie-Oya A, Takakura A, Takao-Kawabata R, et al. Short-term intermittent administration of parathyroid hormone facilitates osteogenesis by different mechanisms in cancellous and cortical bone. Bone reports. 2016;5:7–14. https://doi.org/10.1016/j.bonr.2016.01.002.CrossRefPubMedPubMedCentral

44.

•• Delgado-Calle J, Tu X, Pacheco-Costa R, McAndrews K, Edwards R, Pellegrini GG, et al. Control of bone anabolism in response to mechanical loading and PTH by distinct mechanisms downstream of the PTH receptor. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017;32(3):522–35. https://doi.org/10.1002/jbmr.3011. This study further elucidates the mechanism by which PTH exerts its efficacy. CrossRef

45.

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208743. 2017.

46.

•• Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–33. https://doi.org/10.1001/jama.2016.11136. This is manuscript reports on a clinical trial to deterimine the efficacy of Abaloparatide (PTHrP analog) in postmenopausal osteoporosis. CrossRefPubMed

47.

Wang Y, Fang X, Wang C, Ding C, Lin H, Liu A, et al. Exogenous PTHrP repairs the damaged fracture healing of PTHrP+/− mice and accelerates fracture healing of wild mice. Int J Mol Sci. 2017;18(2) https://doi.org/10.3390/ijms18020337.

48.

Liu A, Li Y, Wang Y, Liu L, Shi H, Qiu Y. Exogenous parathyroid hormone-related peptide promotes fracture healing in Lepr(−/−) mice. Calcif Tissue Int. 2015;97(6):581–91. https://doi.org/10.1007/s00223-015-0041-2.CrossRefPubMed

49.

Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513–23.CrossRefPubMed

50.

Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513–21. https://doi.org/10.1056/NEJMoa013444.CrossRefPubMed

51.

Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537–43.CrossRefPubMed

52.

Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577–89.CrossRefPubMedPubMedCentral

53.

Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2):91–7.CrossRefPubMedPubMedCentral

54.

Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110(2):144–52. https://doi.org/10.1002/ajmg.10401.CrossRefPubMed

55.

•• Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43. https://doi.org/10.1056/NEJMoa1607948. This is manuscript reports on a clinical trial to deterimine the efficacy of Romosozumab (anti-Sclerostin antibody) in postmenopausal osteoporosis. CrossRefPubMed

56.

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20. https://doi.org/10.1056/NEJMoa1305224.CrossRefPubMed

57.

Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19–26. https://doi.org/10.1002/jbmr.173.CrossRefPubMed

58.

Panteli M, Pountos I, Jones E, Giannoudis PV. Biological and molecular profile of fracture non-union tissue: current insights. J Cell Mol Med. 2015;19(4):685–713. https://doi.org/10.1111/jcmm.12532.CrossRefPubMedPubMedCentral

59.

Taylor S, Ominsky MS, Hu R, Pacheco E, He YD, Brown DL, et al. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Bone. 2016;84:148–59. https://doi.org/10.1016/j.bone.2015.12.013.CrossRefPubMed

60.

Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011;26(5):1012–21. https://doi.org/10.1002/jbmr.307.CrossRefPubMed

61.

Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;33(5):747–83. https://doi.org/10.1210/er.2011-1060.CrossRefPubMed

62.

Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, et al. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res. 2011;26(11):2610–21. https://doi.org/10.1002/jbmr.472.CrossRefPubMed

63.

•• Florio M, Gunasekaran K, Stolina M, Li X, Liu L, Tipton B, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016;7:11505. https://doi.org/10.1038/ncomms11505. This is the first publication describing the effect of dual neutralisation of sclerostin and DKK-1 on long bone repair. CrossRefPubMedPubMedCentral

64.

Witcher P, Adaniya A, Adaniya E, Loots G, Robling A, editors. Genetic disruption of compensatory Wnt inhibitor expression reveals a context-dependent, highly osteo-anabolic role for Dkk1 inhibition in the skeleton. ASBMR 2016 Annual Meeting; 2016; Atlanta, U.S.A.

65.

Collette NM, Yee CS, Hum NR, Murugesh DK, Christiansen BA, Xie L, et al. Sostdc1 deficiency accelerates fracture healing by promoting the expansion of periosteal mesenchymal stem cells. Bone. 2016;88:20–30. https://doi.org/10.1016/j.bone.2016.04.005.CrossRefPubMed

66.

Ali IH, Brazil DP. Bone morphogenetic proteins and their antagonists: current and emerging clinical uses. Br J Pharmacol. 2014;171(15):3620–32. https://doi.org/10.1111/bph.12724.CrossRefPubMedPubMedCentral

67.

Tinsley BA, Dukas A, Pensak MJ, Adams DJ, Tang AH, Ominsky MS, et al. Systemic administration of sclerostin antibody enhances bone morphogenetic protein-induced femoral defect repair in a rat model. J Bone Joint Surg Am. 2015;97(22):1852–9. https://doi.org/10.2106/JBJS.O.00171.CrossRefPubMed

68.

Bez M, Sheyn D, Tawackoli W, Avalos P, Shapiro G, Giaconi JC, et al. In situ bone tissue engineering via ultrasound-mediated gene delivery to endogenous progenitor cells in mini-pigs. Sci Transl Med. 2017;9(390):eaal3128. https://doi.org/10.1126/scitranslmed.aal3128.CrossRefPubMedPubMedCentral

69.

Bolander J, Ji W, Leijten J, Teixeira LM, Bloemen V, Lambrechts D, et al. Healing of a large long-bone defect through serum-free in vitro priming of human periosteum-derived cells. Stem cell reports. 2017;8(3):758–72. https://doi.org/10.1016/j.stemcr.2017.01.005.CrossRefPubMedPubMedCentral

70.

Alves RD, Eijken M, Bezstarosti K, Demmers JA, van Leeuwen JP. Activin a suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production. Mol Cell Proteomics. 2013;12(10):2890–900. https://doi.org/10.1074/mcp.M112.024927.CrossRefPubMedPubMedCentral

71.

Sugatani T, Alvarez UM, Hruska KA. Activin a stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem. 2003;90(1):59–67. https://doi.org/10.1002/jcb.10613.CrossRefPubMed

72.

Yamawaki K, Kondo Y, Okada T, Oshima T, Kakitani M, Tomizuka K. The soluble form of BMPRIB is a novel therapeutic candidate for treating bone related disorders. Sci Rep. 2016;6:18849. https://doi.org/10.1038/srep18849.CrossRefPubMedPubMedCentral

73.

Morse A, Cheng TL, Peacock L, Mikulec K, Little DG, Schindeler A. RAP-011 augments callus formation in closed fractures in rats. J Orthop Res. 2016;34(2):320–30. https://doi.org/10.1002/jor.22985.CrossRefPubMed

74.

Bialek P, Parkington J, Li X, Gavin D, Wallace C, Zhang J, et al. A myostatin and activin decoy receptor enhances bone formation in mice. Bone. 2014;60:162–71. https://doi.org/10.1016/j.bone.2013.12.002.CrossRefPubMed

75.

Puolakkainen T, Ma H, Kainulainen H, Pasternack A, Rantalainen T, Ritvos O, et al. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy. BMC Musculoskelet Disord. 2017;18(1):20. https://doi.org/10.1186/s12891-016-1366-3.CrossRefPubMedPubMedCentral

76.

DiGiovanni CW, Petricek JM. The evolution of rhPDGF-BB in musculoskeletal repair and its role in foot and ankle fusion surgery. Foot Ankle Clin. 2010;15(4):621–40. https://doi.org/10.1016/j.fcl.2010.07.001.CrossRefPubMed

77.

Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004;15(4):197–204. https://doi.org/10.1016/j.cytogfr.2004.03.007.CrossRefPubMed

78.

Krell ES, DiGiovanni CW. The efficacy of platelet-derived growth factor as a bone-stimulating agent. Foot Ankle Clin. 2016;21(4):763–70. https://doi.org/10.1016/j.fcl.2016.07.002.CrossRefPubMed

79.

Mehrotra M, Krane SM, Walters K, Pilbeam C. Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells. J Cell Biochem. 2004;93(4):741–52. https://doi.org/10.1002/jcb.20138.CrossRefPubMed

80.

Xie H, Cui Z, Wang L, Xia Z, Hu Y, Xian L, et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat Med. 2014;20(11):1270–8. https://doi.org/10.1038/nm.3668.CrossRefPubMedPubMedCentral

81.

Hollinger JO, Hart CE, Hirsch SN, Lynch S, Friedlaender GE. Recombinant human platelet-derived growth factor: biology and clinical applications. J Bone Joint Surg Am. 2008;90(Suppl 1):48–54. https://doi.org/10.2106/JBJS.G.01231.CrossRefPubMed

82.

Chen W, Baylink DJ, Brier-Jones J, Neises A, Kiroyan JB, Rundle CH, et al. PDGFB-based stem cell gene therapy increases bone strength in the mouse. Proc Natl Acad Sci U S A. 2015;112(29):E3893–900. https://doi.org/10.1073/pnas.1501759112.CrossRefPubMedPubMedCentral

83.

Dodd A, Daniels TR. Injectable recombinant human platelet-derived growth factor in collagen carrier for hindfoot fusion. Foot Ankle Clin. 2016;21(4):777–91. https://doi.org/10.1016/j.fcl.2016.07.013.CrossRefPubMed

84.

Daniels TR, Younger AS, Penner MJ, Wing KJ, Le IL, Russell IS, et al. Prospective randomized controlled trial of hindfoot and ankle fusions treated with rhPDGF-BB in combination with a beta-TCP-collagen matrix. Foot Ankle Int. 2015;36(7):739–48. https://doi.org/10.1177/1071100715576370.CrossRefPubMed

85.

Tickle C, Towers M. Sonic hedgehog signaling in limb development. Front Cell Dev Biol. 2017;5:14. https://doi.org/10.3389/fcell.2017.00014.CrossRefPubMedPubMedCentral

86.

Mak KK, Kronenberg HM, Chuang PT, Mackem S, Yang Y. Indian hedgehog signals independently of PTHrP to promote chondrocyte hypertrophy. Development. 2008;135(11):1947–56. https://doi.org/10.1242/dev.018044.CrossRefPubMed

87.

Lenton K, James AW, Manu A, Brugmann SA, Birker D, Nelson ER, et al. Indian hedgehog positively regulates calvarial ossification and modulates bone morphogenetic protein signaling. Genesis. 2011;49(10):784–96. https://doi.org/10.1002/dvg.20768.CrossRefPubMed

88.

Ito H, Akiyama H, Shigeno C, Iyama K, Matsuoka H, Nakamura T. Hedgehog signaling molecules in bone marrow cells at the initial stage of fracture repair. Biochem Biophys Res Commun. 1999;262(2):443–51. https://doi.org/10.1006/bbrc.1999.1197.CrossRefPubMed

89.

Zou S, Chen T, Wang Y, Tian R, Zhang L, Song P, et al. Mesenchymal stem cells overexpressing Ihh promote bone repair. J Orthop Surg Res. 2014;9:102. https://doi.org/10.1186/s13018-014-0102-7.CrossRefPubMedPubMedCentral

90.

•• Tevlin R, Seo EY, Marecic O, McArdle A, Tong X, Zimdahl B, Malkovskiy A, Sinha R, Gulati G, Li X, Wearda T, Morganti R, Lopez M, Ransom RC, Duldulao CR, Rodrigues M, Nguyen A, Januszyk M, Maan Z, Paik K, Yapa KS, Rajadas J, Wan DC, Gurtner GC, Snyder M, Beachy PA, Yang F, Goodman SB, Weissman IL, Chan CKF, Longaker MT Pharmacological rescue of diabetic skeletal stem cell niches. Sci Transl Med. 2017;9(372). https://doi.org/10.1126/scitranslmed.aag2809. This study details how Ihh can rescue impared fracture repair in diabetic mice.

91.

Jiao H, Xiao E, Graves DT. Diabetes and its effect on bone and fracture healing. Curr Osteoporos Rep. 2015;13(5):327–35. https://doi.org/10.1007/s11914-015-0286-8.CrossRefPubMedPubMedCentral

92.

Ornitz DM, Legeai-Mallet L. Achondroplasia: development, pathogenesis, and therapy. Developmental dynamics: an official publication of the American Association of Anatomists. 2017;246(4):291–309. https://doi.org/10.1002/dvdy.24479.CrossRef

93.

Makrythanasis P, Temtamy S, Aglan MS, Otaify GA, Hamamy H, Antonarakis SE. A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly. Hum Mutat. 2014;35(8):959–63. https://doi.org/10.1002/humu.22597.CrossRefPubMed

94.

Rundle CH, Miyakoshi N, Ramirez E, Wergedal JE, Lau KH, Baylink DJ. Expression of the fibroblast growth factor receptor genes in fracture repair. Clin Orthop Relat Res. 2002;403:253–63.CrossRef

95.

Fei Y, Gronowicz G, Hurley MM. Fibroblast growth factor-2, bone homeostasis and fracture repair. Curr Pharm Des. 2013;19(19):3354–63.CrossRefPubMed

96.

Xiao L, Liu P, Li X, Doetschman T, Coffin JD, Drissi H, et al. Exported 18-kDa isoform of fibroblast growth factor-2 is a critical determinant of bone mass in mice. J Biol Chem. 2009;284(5):3170–82. https://doi.org/10.1074/jbc.M804900200.CrossRefPubMedPubMedCentral

97.

Xiao L, Ueno D, Catros S, Homer-Bouthiette C, Charles L, Kuhn L, et al. Fibroblast growth factor-2 isoform (low molecular weight/18 kDa) overexpression in preosteoblast cells promotes bone regeneration in critical size calvarial defects in male mice. Endocrinology. 2014;155(3):965–74. https://doi.org/10.1210/en.2013-1919.CrossRefPubMedPubMedCentral

98.

Hurley MM, Adams DJ, Wang L, Jiang X, Burt PM, Du E, et al. Accelerated fracture healing in transgenic mice overexpressing an anabolic isoform of fibroblast growth factor 2. J Cell Biochem. 2016;117(3):599–611. https://doi.org/10.1002/jcb.25308.CrossRefPubMed

99.

Shah P, Keppler L, Rutkowski J. A review of platelet derived growth factor playing pivotal role in bone regeneration. J Oral Implantol. 2014;40(3):330–40. https://doi.org/10.1563/AAID-JOI-D-11-00173.CrossRefPubMed

100.

Kronenberg HM. Developmental regulation of the growth plate. Nature. 2003;423(6937):332–6. https://doi.org/10.1038/nature01657.CrossRefPubMed

101.

Karp SJ, Schipani E, St-Jacques B, Hunzelman J, Kronenberg H, McMahon AP. Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and -independent pathways. Development. 2000;127(3):543–8.PubMed

102.

Nakajima F, Ogasawara A, Goto K, Moriya H, Ninomiya Y, Einhorn TA, et al. Spatial and temporal gene expression in chondrogenesis during fracture healing and the effects of basic fibroblast growth factor. J Orthop Res. 2001;19(5):935–44. https://doi.org/10.1016/S0736-0266(01)00024-9.CrossRefPubMed

103.

Shimoaka T, Ogasawara T, Yonamine A, Chikazu D, Kawano H, Nakamura K, et al. Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10. J Biol Chem. 2002;277(9):7493–500. https://doi.org/10.1074/jbc.M108653200.CrossRefPubMed

104.

Einhorn TA, Gerstenfeld LC. Fracture healing: mechanisms and interventions. Nat Rev Rheumatol. 2015;11(1):45–54. https://doi.org/10.1038/nrrheum.2014.164.CrossRefPubMed

105.

Poniatowski LA, Wojdasiewicz P, Gasik R, Szukiewicz D. Transforming growth factor Beta family: insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications. Mediat Inflamm. 2015;2015:137823–17. https://doi.org/10.1155/2015/137823.CrossRef

Title: Anabolic Strategies to Augment Bone Fracture Healing
Authors: Scott J. Roberts
Hua Zhu Ke
Publication date: 01-06-2018
Publisher: Springer US
Published in: Current Osteoporosis Reports / Issue 3/2018
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-018-0440-1

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Anabolic Strategies to Augment Bone Fracture Healing

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2018

The Role of Matrix Composition in the Mechanical Behavior of Bone

Human Genetics of Sclerosing Bone Disorders

Regenerative Medicine Strategies in Biomedical Implants

Clinical Management of Osteoporotic Fractures

Epigenetics of Skeletal Diseases

Low-Magnitude Forces for Bone Modeling and Remodeling in Dentofacial Orthopedics